hENT1 predicts benefit from gemcitabine in pancreatic cancer but only with low CDA mRNA
Authors
Aughton, K.Elander, N. O.
Evans, A.
Jackson, R.
Campbell, F.
Costello, E.
Halloran, C. M.
Mackey, J. R.
Scarfe, A. G.
Valle, Juan W
Carter, R.
Cunningham, D.
Tebbutt, N. C.
Goldstein, D.
Shannon, J.
Glimelius, B.
Hackert, T.
Charnley, R. M.
Anthoney, A.
Lerch, M. M.
Mayerle, J.
Palmer, D. H.
Buchler, M. W.
Ghaneh, P.
Neoptolemos, J. P.
Greenhalf, W.
Affiliation
Liverpool Experimental Cancer Medicine Centre, 2nd Floor Sherrington Building, Ashton St, University of Liverpool, Liverpool L69 3GE, UKIssue Date
2021
Metadata
Show full item recordCitation
Aughton K, Elander NO, Evans A, Jackson R, Campbell F, Costello E, et al. hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA Vol. 13, Cancers. MDPI AG; 2021. p. 5758.Journal
CancersDOI
10.3390/cancers13225758PubMed ID
34830914Type
Articleae974a485f413a2113503eed53cd6c53
10.3390/cancers13225758
Scopus Count
Collections
Related articles
- Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer.
- Authors: Elander NO, Aughton K, Ghaneh P, Neoptolemos JP, Palmer DH, Cox TF, Campbell F, Costello E, Halloran CM, Mackey JR, Scarfe AG, Valle JW, McDonald AC, Carter R, Tebbutt NC, Goldstein D, Shannon J, Dervenis C, Glimelius B, Deakin M, Charnley RM, Anthoney A, Lerch MM, Mayerle J, Oláh A, Büchler MW, Greenhalf W, European Study Group for Pancreatic Cancer
- Issue date: 2018 Apr
- Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer.
- Authors: Farrell JJ, Elsaleh H, Garcia M, Lai R, Ammar A, Regine WF, Abrams R, Benson AB, Macdonald J, Cass CE, Dicker AP, Mackey JR
- Issue date: 2009 Jan
- Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial.
- Authors: Greenhalf W, Ghaneh P, Neoptolemos JP, Palmer DH, Cox TF, Lamb RF, Garner E, Campbell F, Mackey JR, Costello E, Moore MJ, Valle JW, McDonald AC, Carter R, Tebbutt NC, Goldstein D, Shannon J, Dervenis C, Glimelius B, Deakin M, Charnley RM, Lacaine F, Scarfe AG, Middleton MR, Anthoney A, Halloran CM, Mayerle J, Oláh A, Jackson R, Rawcliffe CL, Scarpa A, Bassi C, Büchler MW, European Study Group for Pancreatic Cancer
- Issue date: 2014 Jan
- Human equilibrative nucleoside transporter 1 is not predictive for gemcitabine efficacy in advanced pancreatic cancer: translational results from the AIO-PK0104 phase III study with the clone SP120 rabbit antibody.
- Authors: Ormanns S, Heinemann V, Raponi M, Isaacson J, Laubender RP, Haas M, Kruger S, Kleespies A, Mann E, Bartosiewicz M, Kirchner T, Boeck S
- Issue date: 2014 Jul
- Tailored adjuvant gemcitabine versus 5-fluorouracil/folinic acid based on hENT1 immunohistochemical staining in resected pancreatic ductal adenocarcinoma: A biomarker stratified prospective trial.
- Authors: Shin DW, Lee JC, Kim J, Yoon YS, Han HS, Kim H, Hwang JH
- Issue date: 2021 Jun